Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Quantum Biopharma ( (TSE:QNTM) ) has issued an announcement.
On May 12, 2025, Quantum BioPharma announced the completion of dosing in 90-day oral toxicity and toxicokinetic studies for its drug Lucid-21-302 (Lucid-MS), aimed at treating Multiple Sclerosis. This milestone supports their IND application with the US FDA and brings them closer to initiating a Phase 2 trial, potentially enhancing their position in the biopharmaceutical industry.
More about Quantum Biopharma
Quantum BioPharma Ltd. is a biopharmaceutical company focused on developing innovative assets and biotech solutions for neurodegenerative, metabolic, and alcohol misuse disorders. The company is advancing its lead compound, Lucid-MS, which has shown potential in preventing and reversing myelin degradation in multiple sclerosis.
YTD Price Performance: 115.38%
Average Trading Volume: 9,085
Technical Sentiment Signal: Sell
Current Market Cap: C$28.98M
For an in-depth examination of QNTM stock, go to TipRanks’ Stock Analysis page.